Eli Lilly Launches $1 Billion AI-Powered Drug Discovery Platform

Eli Lilly launches platform for AI-enabled drug discovery

Sept 9 (Reuters) - Drugmaker Eli Lilly (LLY.N), opens new tab said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of its research data. Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future. Lilly's platform, TuneLab, consists of AI models which include proprietary data obtained at a cost of over $1 billion. "Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists," said chief scientific officer Daniel Skovronsky. Privately held companies Circle Pharma and insitro said they are partnering with Lilly to develop cancer therapies and small molecule drugs, respectively. Reporting by Christy Santhosh in Bengaluru; Editing by Harikrishnan Nair and Krishna Chandra Eluri Our Standards: The Thomson Reuters Trust Principles., opens new tab

Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data - Eli Lilly (NYSE:LLY)

Eli Lilly and Co. LLY on Tuesday launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data. Eli Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion. "Lilly has spent decades building comprehensive datasets for drug discovery. Today, we're sharing the intelligence gained from that investment to help lift the tide of biotechnology research," said Daniel Skovronsky, chief scientific officer and president, Lilly Research Laboratories and Lilly Immunology. Lilly TuneLab is powered by Lilly's comprehensive drug disposition, safety, and preclinical datasets, which represent experimental data obtained with hundreds of thousands of unique molecules. Also Read: Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients. The platform is hosted by a third-party and employs federated learning, a privacy-preserving approach that enables biotechs to tap into Lilly's AI models without directly exposing their proprietary data or Lilly's. Lilly intends to extend the platform's features and capabilities beyond this first release, including adding in vivo small molecule predictive models, available exclusively on Lilly TuneLab. Price Action: LLY stock is up 0.19% at $740.02 during the premarket session at the last check on Tuesday. Read Next: FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List Image: Shutterstock LLYEli Lilly and Co$746.101.01%Stock Score Locked: Edge Members Only Benzinga Rankings give you vital metrics on any stock - anytime. Unlock RankingsEdge RankingsMomentum16.42Growth99.50Quality89.46Value2.68Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs